Key result
Exenatide significantly improved heart function in diabetic rats by down-regulating myocardial adiponectin receptor 1, p22phox, and NOX4, independent of blood glucose lowering.
Why the study?
Does exenatide improve heart function and alter cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits in streptozotocin-induced diabetic rats?
Population
Male Sprague-Dawley rats with streptozotocin-induced diabetes and non-diabetic controls.
Comparison
Exenatide injected subcutaneously twice daily… vs Diabetic rats injected subcutaneously with…
Design
Preclinical, Randomly divided into groups, Quantification was performed with…
Follow-up
8 weeks
Authors
Loading...
Should not change clinical practice in diabetic cardiomyopathy; leaves open human translation of exenatide's effects.
Does exenatide improve heart function and alter cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits in streptozotocin-induced diabetic rats?
Absolute Event Rate: 102.42% vs 78.77%
p-value: p=<0.05
Exenatide improves heart function in a rat model of type 1 diabetes through antioxidative actions and regulation of adiponectin receptors, independent of glycemic control.
Guo et al. (2014) studied Streptozotocin-induced diabetes (n=36). Exenatide vs. Normal saline (untreated diabetic control) was evaluated on Left ventricular systolic pressure (LVSP) (p=<0.05). Exenatide significantly improved heart function in diabetic rats by down-regulating myocardial adiponectin receptor 1, p22phox, and NOX4, independent of blood glucose lowering.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: